{"filings":[{"id":93089,"accession_number":"0001193125-26-206455","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q1 revenue $70.9M, up 35% YoY; MRD revenue up 53%; raises FY2026 MRD guidance to $260-270M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $70.9M (+35% YoY); MRD revenue $67.1M (+53% YoY); clonoSEQ test volume 32,595 (+41%).","Net loss narrowed to $20.0M from $29.8M; adj. EBITDA loss $2.5M improved from $12.7M loss.","Raised FY2026 MRD revenue guidance to $260-270M (from $255-265M), implying 22-27% annual growth.","Recognized $9.0M in MRD pharma regulatory milestone revenue, first U.S. primary endpoint milestone.","Immune Medicine revenue $3.8M (-57% YoY); cash & equivalents $237.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":70874000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104419,"accession_number":"0001193125-26-039409","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q4 rev $71.7M (+51% YoY); MRD profitable; FY2026 MRD rev guide $255-265M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $71.7M (+51% YoY); FY revenue $277.0M (+55% YoY); net loss narrowed to $13.6M and $59.5M.","MRD segment achieved positive Adjusted EBITDA and cash flow; MRD revenue Q4 $61.9M (+54%), FY $212.3M (+46%).","clonoSEQ test volume Q4 30,038 (+43% YoY); FY 105,587 (+39% YoY); expanded Medicare coverage in mantle cell lymphoma.","Signed two non-exclusive immune receptor data licensing agreements with Pfizer.","FY2026 guidance: MRD revenue $255-265M; total OpEx $350-360M; management expects company-wide profitability in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":276976000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104418,"accession_number":"0001193125-26-009840","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Adaptive Biotechnologies reports preliminary Q4/FY2025 revenue growth of 51%/55% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue FY2025 ~$277M (+55% YoY); Q4 ~$72M (+51% YoY).","MRD revenue FY2025 ~$212M (+46% YoY); excluding milestone revenue grew 45%.","clonoSEQ test volume FY2025 ~105,600 tests (+39% YoY); Q4 ~30,000 tests (+43% YoY).","Cash, cash equivalents and marketable securities ~$227M as of Dec 31, 2025.","Company expects full FY2025 net loss to decrease vs 2024; complete results due Feb 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":276976000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120710,"accession_number":"0001193125-25-335921","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Adaptive Biotechnologies subsidiary Digital Biotechnologies closes Series A up to $15M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Digital Biotechnologies, 70%-owned subsidiary, held initial closing of Series A Preferred Stock financing.","Anticipated total proceeds of up to $15 million from the Series A round.","Upon completion, Adaptive expects to retain nearly 50% ownership and continue consolidating Digital's results.","Digital Biotechnologies is an early-stage company with no revenues and limited activities to date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120709,"accession_number":"0001193125-25-266974","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q3 revenue $94M (+102% YoY); MRD profitable, guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $94.0M (up 102% YoY) includes $33.7M from full amortization of Genentech payment.","MRD revenue $56.8M (+52% YoY); MRD achieved profitability and cash flow positivity with Adj. EBITDA $7.0M.","clonoSEQ test volume 27,111 (+38% YoY); NCCN guidelines updated for CLL MRD-guided treatment duration.","Net income $9.5M vs $32.1M loss in Q3 2024; Adj. EBITDA $28.0M vs $14.3M loss.","FY2025 MRD revenue guidance raised to $202-207M; total operating spend and cash burn guidance reduced."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":205295000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137302,"accession_number":"0001193125-25-182222","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Adaptive and Genentech terminate cell therapy collaboration; $33.7M non-cash revenue in H2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Strategic Collaboration and License Agreement with Genentech terminated Aug 13, 2025; effective Feb 9, 2026.","Adaptive expects $33.7M non-cash revenue in H2 2025 from remaining amortization of cash consideration.","Company released from exclusivity obligations in oncology cell therapies.","Ongoing Immune Medicine programs: digital TCR-antigen models, T-cell depletion in autoimmunity, FY2025 cash burn target $25-30M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137301,"accession_number":"0000950170-25-103058","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Q2 MRD revenue up 42%, achieves MRD profitability; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $58.9M (+36% YoY); MRD revenue $49.9M (+42% YoY); MRD Adjusted EBITDA positive $1.9M.","clonoSEQ volume 25,321 (+37% YoY); Immune Medicine revenue $8.9M (+13% YoY).","Net loss $25.6M ($46.2M in Q2 2024); Adjusted EBITDA loss $7.2M vs $21.4M prior year.","FY 2025 MRD revenue guidance raised to $190-200M (from $180-190M); cash burn guidance lowered to $45-55M.","Cash $222M; launched clonoSEQ integration into Flatiron OncoEMR; recognized $5.5M pharma milestone revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":111322000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154616,"accession_number":"0001193125-25-140017","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Adaptive Biotechnologies shareholders elect Chad Robins and approve say-on-pay, auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Chad Robins elected Class III director with 80.95% of votes cast; 12.8M broker non-votes.","Say-on-pay advisory proposal passed with 98.46% support; 1.23% against.","Ratification of Ernst & Young as 2025 auditor approved with 99.91% of votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154615,"accession_number":"0000950170-25-061851","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q1 revenue up 25% to $52.4M; raises MRD guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $52.4M (+25% YoY); MRD revenue $43.7M (+34%); clonoSEQ volume up 36% to 23,117 tests.","Net loss narrowed to $29.8M from $47.5M; adjusted EBITDA loss $12.7M from $28.2M.","Raises FY 2025 MRD revenue guidance to $180-190M (from $175-185M); lowers cash burn target to $50-60M.","Expanded Medicare coverage for clonoSEQ in mantle cell lymphoma recurrence monitoring.","Cash, equivalents, and marketable securities $232.8M at March 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":52443000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173144,"accession_number":"0000950170-25-017915","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotech Q4 revenue $47.5M; MRD revenue up 31% YoY; FY2025 MRD guidance $175-185M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $47.5M (+4% YoY); full year $179.0M (+5%). MRD revenue $40.1M (+31% Q4, +42% FY).","clonoSEQ test volume Q4 20,945 tests (+34% YoY); full year 76,105 tests (+35%).","Net loss Q4 $33.7M vs $69.5M a year ago; FY net loss $159.6M vs $225.3M. Adjusted EBITDA loss Q4 $16.4M vs $24.7M.","FY2025 guidance: MRD revenue $175-185M; total operating expenses $340-350M; cash burn $60-70M.","FDA ODAC unanimously voted to support MRD as primary endpoint for accelerated approval in multiple myeloma."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":178957000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190169,"accession_number":"0000950170-24-123369","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q3 revenue $46.4M (+22%); MRD revenue up 52%; net loss narrows to $32.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $46.4M (+22% YoY); MRD revenue $37.5M (+52%); Immune Medicine $9.0M (-32%).","Net loss $32.1M vs $50.3M YoY; Adjusted EBITDA loss $14.3M vs $29.8M.","clonoSEQ test volume 19,600 (+30%); Medicare gapfill rate raised 17% to $2,007/test.","MRD revenue guidance raised to $143-145M (prev. $140-145M); op. expense guidance cut to $335-340M.","Cash, cash equivalents and marketable securities $267.2M; interest expense on revenue interest purchase $2.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":131498000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206677,"accession_number":"0000950170-24-089301","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q2 MRD revenue up 36% YoY; updates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q2 revenue $43.2M (-12% YoY); MRD revenue $35.3M (+36%), Immune Medicine $7.9M (-66%).","Net loss $46.2M vs $47.8M YoY; Adjusted EBITDA loss $21.4M vs $24.8M.","clonoSEQ test volume 18,520 (+36% YoY); recognized $3.0M MRD regulatory milestone.","FY 2024 MRD revenue guidance raised to $140-145M (from $135-140M); total OPEX guidance lowered to $340-350M.","Cash and securities $291.9M as of June 30."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":85063000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223873,"accession_number":"0000950170-24-071913","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Shareholders elect directors with majority support; Nasdaq confirms audit committee compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Peter Neupert elected with 69.15% for (30.85% withhold); Michelle Griffin with 82.93% for.","Advisory vote on 2023 executive compensation passed with 86% support.","Ratification of Ernst & Young as independent auditor for FY2024 passed with 99.6% approval.","Nasdaq confirmed compliance with Listing Rule 5605(c)(2) after Peter Neupert joined audit committee in July 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223872,"accession_number":"0000950170-24-054513","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies Q1 2024: MRD revenue up 52% to $32.6M; net loss narrows to $47.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $41.9M (+11% YoY); MRD $32.6M (+52%), Immune Medicine $9.2M (-43%).","clonoSEQ test volume rose 41% to 17,040; net loss improved to $47.5M from $57.7M.","Cash $308.9M; FY2024 MRD revenue guidance raised to $135-140M, opex lowered to $350-360M.","FDA ODAC unanimously supported MRD as primary endpoint for accelerated approval in multiple myeloma.","Strategic move: MRD and Immune Medicine to report separately; antibody discovery launched for MS and type 1 diabetes."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":41873000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223871,"accession_number":"0001193125-24-090983","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Adaptive Biotechnologies appoints Kyle Piskel as CFO effective April 8, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kyle Piskel promoted from Principal Accounting Officer to CFO; reports to CEO Chad Robins.","Base salary set at $380,000 per year; target bonus of 40% of eligible earnings.","Receives RSU grant of 31,260 shares (4-year vesting) and PSU grant of 75,000 shares (3-year performance period).","Also entitled to annual equity refresh of 43,740 RSUs, bringing 2024 total equity grants to 150,000 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223870,"accession_number":"0000950170-24-042291","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotech Q1 prelim rev ~$41-43M (+12% YoY); CFO Peterson departs, Piskel named","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary total Q1 2024 revenue of ~$41-43M, up ~12% vs Q1 2023.","MRD revenue ~$31-32M, up ~47% YoY; Immune Medicine revenue implied by difference.","Strategic review concludes: run MRD and Immune Medicine internally with separate resources and segment reporting.","CFO Tycho Peterson departs; Kyle Piskel (Principal Accounting Officer, 8-yr tenure) appointed full-time CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223869,"accession_number":"0001193125-24-084748","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Tycho Peterson resigns; Kyle Piskel named CFO effective April 8","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tycho Peterson resigned as CFO effective April 5, 2024; resignation voluntary with no disagreement.","Kyle Piskel, current Principal Accounting Officer and 8-year veteran, appointed CFO starting April 8, 2024.","No other leadership changes or compensatory arrangements disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243257,"accession_number":"0000950170-24-015230","cik":1478320,"company_name":"Adaptive Biotechnologies Corp","ticker":"ADPT","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adaptive Biotech Q4 revenue down 17% to $45.8M; net loss widens to $69.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2023 revenue $170.3M (-8% YoY); MRD revenue $102.7M (+18%) offset by IM decline.","clonoSEQ test volume up 53% YoY to 56,496 tests delivered in 2023.","Net loss $225.3M in 2023 vs $200.4M in 2022; includes $25.4M lease impairment charge.","Adjusted EBITDA loss $116.4M in 2023 vs $121.6M loss in 2022.","2024 MRD revenue guidance $130-140M; total OpEx guided to $360-370M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":170276000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2384661404.971099,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}